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sults There was no signiﬁcant difference between the 3 groups in
the occurrence of FN or documented infection. However, hyper-
glycemia was signiﬁcantly associated with organ dysfunction and
aGVHD. OS was better and TRM was less in group1 compared
with group2 and group3. Conclusion Degrees of hyperglycemia
during neutropenia was associated with an increased risk of organ
dysfunction and aGVHD, which further led to higher TRM and
lower OS. These results support the possibility that intensive
glucose control reduces morbidity and mortality after HSCT.
blood glucose level
normoglycemia
(n28)
mild
hyperglycemia
(n49)
moderate and
severe
hyperglycemia
(n14)
FN 25 (89%) 43 (88%) 13 (93%)
Documented infection 9 (32%) 10 (20%) 6 (43%)
hypercreatininemia (serum
creatinine>2mg/dl or
more than twice of
baseline) 1 (4%) 4 (8%) 4 (29%)
hyperbilirubinemia (serum
bilirubin>2 mg/dl) 3 (11%) 11 (22%) 6 (43%)
CRP elevation (serum
CRP>15 mg/dl) 4 (14%) 15 (31%) 9 (64%)
aGVHD (II-IV) 4 (14%) 18 (38%) 7 (58%)
OS (1-year) 87% 70% 56%
TRM (1-year) 5% 17% 30%
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THROMBOTIC MICROANGIOPATHY AFTER HSCT: MUCOSITIS AS A RISK
FACTOR FOR SURVIVAL AND HIGH PREVALENCE OF ACUTE GVHD, CMV
AND GRAM POSITIVE INFECTIONS
Funke, V.A.M.1, Oliveira, M.M.1, Ruiz, J.1, Bonﬁm, C.M.1,
Bitencourt, M.A.1, Coutinho, E.N.1, Setubal, D.C.1, Zanis-Neto, J.1,
de Medeiros, C.P.1, Pasquini, R.1 1Hospital de Clinicas - Universidade
Federal do Parana, Curitiba, PR, Brazil.
INTRODUCTION: Thrombotic microangiopathy is a rare
complication after HSCT. Given the different pathophisiology of
the disease and high mortality observed, our purpose is evaluating
clinical carcteristcs of these patients and risk factors for survival.
PATIENTS AND METHODS: From 1991to 2004, 1066
HSCT were performed at HC-UFPR (Curitiba, Brazil). We iden-
tiﬁed in our database 17 patients with the diagnosis of thrombotic
microangiopathy (prevalence of 1.6%). M4/F13, Median
age(y)11; Diagnosis included: SAA: 2; Fanconi anemia: 4; Acute
leukemias: 7, Others 2.
Conditioning regimen consisted of BUCY in 9/17 (52%); CI 
TBI in 3/17 (18%) of the patients, NMA regimens in 18% and
others in 12% of the patients. Immunephrophylaxis
consisted of CSA and MTX in 52% of the patients.Twelve
patients received related and ﬁve received unrelated donor trans-
plant.
Marrow was the stem cell source in all but one patient who
received cord blood.
Twelve patients were HLA identical, three patients had a class
one mismatch, one patients had a class II mismatch and one patient
had more than one mismatch.
Median number of cells infused were 2,57  108/KG.
RESULTS A-GVHD grade II-IV was present in 12 (70%) pa-
tients and extensive C-GVHD was present in only 18% of the
patients. Median survival was 99 days and estimated overall survival
in 25 years is only 15%, despite therapy. Infection was present in
all but one patient (94%). Ten patients had serious bacterial in-
fections (58%), eight of them by gram-positive bacteria. Fungal
infection was identiﬁed in ﬁve patients (2 Candida sp and 3 As-
pergillus sp). Viral infection was identiﬁed in 12 patients (eight of
them with CMV positive antigenemia). Causes of death included:
A-GVHD in four pt, C-GVHD in 2 patients, infection in 6
patients, bleeding in two patients and persistent disease in one
patient. The only signiﬁcant factor for survival was severe mucosi-
tis (more than grade II).
CONCLUSION: 1. OS was extremely low (15%) despite ther-
apy; 2. Infection ( specially gram-positive bacterial infections and
CMV positive antigenemia) was present at the majority of the
patients and was the main cause of death; 3. A-GVHD was present
in 52% of the patients; 4. Severe mucositis was associated to a
lower survival rate (p0,02).
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LONG TERM RESULTS OF ALLOGENEIC STEM CELL TRANSPLANT FOR
CML IN PEDIATRIC PATIENTS: A STUDY OF 50 CASES TRANSPLANTED
OVER 20 YEARS IN A SINGLE INSTITUTION
Funke, V.A.M.1, Pettengill, C.1, Bonﬁm, C.M.1, Ruiz, J.1,
Azambuja, A.P.1, Medeiros, L.1, Setubal, D.C.1, Bitencourt, M.A.1,
Oliveira, M.M.1, Coutinho, E.N.1, Zanis-neto, J.1, de Medeiros, C.P.1,
Pasquini, R.1 1Hospital de Clinicas - Universidade Federal do Parana,
Curitiba, PR, Brazil.
Introduction: Chronic myeloid leukemia (CML) accounts for
2-3% of the leukemias in childhood. The only potential curative
treatment is allogeneic hematopoietic stem cell transplantation
(HSCT), although promising results achieved with imatinib me-
sylate in adults substantiate its use as a therapeutic alternative for
children. The aim of this study is to analyze the outcomes of
HSCT in pediatric patients regarding overall survival (OS) and
main causes of death.
Materials and methods: Retrospective analysis of children aged
1-17 years, diagnosed with CML who underwent HSCT in a single
institution in Brazil between jan/1984 and aug/2005. Survival was
estimated by Kaplan-Meier curves. Log Rank test was used for
comparison of continuous variables.
Results: Fifty patients were assessed, 31 male and 19 female.
Median age of 13,5 years (1-17). Forty one patients (82%) were in
ﬁrst chronic phase (CP1) and 9 in advanced phases. The interval
between diagnosis and HSCT had a median time of 17,5 months
(5-84). The source of stem cells was bone marrow in 44 patients
(88%), umbilical cord blood in 5 (10%) and peripheral blood stem
cell in 1 (2%). Thirty nine patients (78%) underwent related
HSCT and 11 (22%) unrelated donor HSCT. Conditioning reg-
imens: busulfan and cyclophosphamide in 35 patients (70%) and
TBI containing regimens in 15 (30%). Complete engraftment
occurred in 82% of the transplants. Acute (a) graft-versus-host-
disease (GVHD) grades II-IV occurred in 44% of the patients,
with 20% grade IV. Extensive chronic (c) GVHD occurred in
15/40 patients (38%). Fifteen patients (32%) relapsed after HSCT.
Mortality in the study population was 48% and the main causes of
death were: relapse in 6 patients (25%), a-GVHD in 6 (25%) and
c-GVHD in 4 (17%). Estimated OS in 20 years was 50%, with a
median survival of 1926 days. When analyzed separately, patients
in CP1 who received related HSCT and immuneprophilaxis with
three drugs (steroids, cyclosporine and methotrexate) had an esti-
mated OS in 20 years of 70%.
Conclusions: 1) Long term follow up of these children with
CML who underwent allogeneic HSCT demonstrate an OS of
50%, reaching 70% in low risk patients. 2) Main causes of death
were relapse, acute and chronic GVHD.
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RISK FACTOR ANALISIS FOR SURVIVAL IN 125 UNRELATED TRANS-
PLANTS FOR MALIGNANT DISEASES PERFORMED OVER TEN YEARS IN
A SINGLE CENTER IN BRAZIL
Funke, V.A.M.1, Coutinho, E.N.1, Setubal, D.C.1, Ruiz, J.1,
Bonﬁm, C.M.1, Bittencourt, M.A.1, Oliveira, M.M.1, Zanis-Neto, J.1,
de Medeiros, C.P.1, Pasquini, R.1 1Hospital de Clinicas - Universidade
Federal do Parana, Curitiba, PR, Brazil.
INTRODUCTION: Unrelated transplants are incresingly used
for therapy of malignant diseases. The objective of this study is
evaluating risk factors for overall survival among 125 unrelated
transplants performed at the BMT center of HC-UFPR in Cu-
ritiba, Brazil.
PATIENTS AND METHODS: we analyzed results of unre-
lated HSCT performed from 07/95 to 06/05.Kaplan Meier was
used to estimate overall survival. Log rank test was used to compare
survival curves and Fisher’s exact test for comparison of categoric
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variables. Cox proportional harzards model was used to identify
risk factors for survival. Analyzed risk factors were: age, sex, diag-
nosis, disease stage, acute GVHD (grade II-IV), extensive
c-GVHD, stem cell source (cord blood x bone marrow), use of
antibodies directed to T-cells and HLA matching. Diagnosis were:
CML-46; AML/MDS-40, ALL-34, OTHERS-5. Male: 78; fe-
male: 44; median age 17 years (range: 1-55). Cell source was bone
marrow in 95 patients, cord blood in 30 patients. Conditioning
regimen was nomyeloablative in 8 patients and conventional in 114
patients. 25 patients received ATG or ALG as part of their con-
ditioning regimen and 90 patients received cyclophosphamide and
TBI. Sixty-six patients (53%) had advanced disease at the time of
transplant (CML advanced phase, AML or ALL in  second
remission, relapsed or refractory).
RESULTS: Acute GVHD grade II-IV was observed in 51 pa-
tients (41%) and was the primary cause of death in 9% of the
patients. Extensive chronic GVHD was observed in 32 patients
(26%) and was the primary cause of death in 13% of the patients.
Other causes of death included: infection in 32 (41%) and relapse
in 21 (27%) of the patients. Estimated 10 years overall survival was
40% with a median survival of 189 days. There was no difference
in survival according sex, diagnosis, stem cell source, type of con-
ditioning, number of cells infused or HLA compatibility. There
was a signiﬁcant better 10 years survival for early disease, compared
to advanced disease (55% x 20%; p0.0005), age less than 18 x
more than 18 (60% x 20%; p0.0012). Extensive c-GVHD was
protective for overall survival (P0.0340; Odds ratio 0.3998;
95% CI0.1758 to 0.9092).
CONCLUSIONS: 1) Estimated 10 y overall survival was 55%
for patients with early disease; 2) Extensive c-GVHD had a pro-
tective effect on OS, probably due to graft versus malignant effect.
3) Age less than 18 years and early disease were favorable risk
factors for survival.
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PLATEAU IN THE DISEASE-FREE SURVIVAL CURVE AFTER ALLOGENEIC
STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID
LEUKEMIA MAY SIGNIFY CURE: A LONG-TERM SINGLE INSTITUTION
EXPERIENCE
Ganguly, S.1, Divine, C.L.1, Deauna-Limayo, D.1,
Bodensteiner, D.C.1, Lewis, J.L.1, Hoffmann, T.1, Curran, K.1,
Skikne, B.S.1 1University of Kansas Medical Center, Kansas City, KS.
Introduction: Allogeneic Stem Cell Transplantation (AlloSCT)
through the graft-versus-leukemia (GVL) effect holds the promise
of a long-term cure in patients with acute myeloid leukemia
(AML).
Methods: In an attempt to examine whether AlloSCT provides
long-term disease control in patients with AML, we retrospectively
evaluated our experience and analyzed the outcomes of ASCT in
patients with AML from 1978 to 2005.
Results: Fifty-nine males and 46 females (n105) of median age
32 years (range: 5-60 years) were treated. Of these, 65 were in CR
at the time of transplantation, 40 patients were transplanted with
active disease. Fifty patients were transplanted in ﬁrst remission.
Bone marrow was used in 75 patients as the source of stem cells
prior to 1995 and peripheral blood stem cells (PBSC) were used in
30 patients. Ninety-four of 105 patients engrafted (90%). Median
time for neutrophil recovery was 16 days (range: 9-90 days) and 23
days (range: 9-106 days) for platelets. Median duration of fol-
low-up for those who did not succumb to early transplant-related
mortality (100 days) was 2 years (range: 102 days-21 years).
Median survival time of this cohort was 2 years. Of the 105
patients, 77 have died. Thirty-four patients (32%) died within
100-days of transplantation. Overall survival (OS) of all patients
who did not succumb to TRM was 47% at 5-years, 38% at
10-years and 15-years respectively. No relapse occurred after 4.25
years. OS in patients transplanted in CR (n65) at 5-years was
72%, and at 10 and 15-years was 62% respectively. For those
transplanted with disease (n40), a complete response was
achieved in 23 patients (22%), with a median survival of 214 days.
Disease status at transplantation was a signiﬁcant variable for
survival (p0.01). Most frequent cause of death was infection (27
out of 105 patients). Five patients developed late onset myelodys-
plastic syndrome/secondary malignancy. Patients with any graft-
versus-host-disease (GVHD) had better survival compared to pa-
tients with no GVHD, underscoring the role of GVL effect in
long-term disease control.
Conclusion: In conclusion, AlloSCT provides a possible cure in
a proportion of patients with AML as evidenced by a plateau in the
DFS curve after 4.25 years.
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REDUCED-INTENSITY STEM CELL TRANSPLANTATION IN PATIENTS
WITH HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
Gutierrez-Aguirre, C.H.1, Ruiz-Argu¨elles, G.J.2, Cantu-Rodriguez, O.G.1,
Gonzalez-LLano, O.1, Gomez-Almaguer, D.1 1Servicio de Hematologia del
Hospital Universitario de la U.A.N.L., Monterrey, Nuevo Leon, Mexico;
2Centro de Hematologia y Medicina Interna de Puebla, Puebla, Mexico.
Introduction: Despite the optimal use of the antileukemic
agents, reported cure rates no exceed 40% in high-risk ALL adult
patients. The use of hematopoietic stem cell transplantation
(HSCT) is other option in these patients and non-myeloablative
conditioning is a friendly alternative to the conventional and more
toxic myeloablative radio-chemtotherapy scheme, but there is very
limited information using this kind of transplantation in ALL. We
prospectively evaluated the therapeutic value of non-myeloablative
conditioning HSCT in 43 high risk ALL patients in second or
subsequent remission. Patients and methods. Forty three ALL
high-risk patients were prospectively allografted, using HLA-iden-
tical siblings as donors. Patients received oral busulphan 4 mg /
Kg/2 days, i.v. cyclophosphamide 350 mg /m2/3 days and i.v.
ﬂudarabine 30 mg /m2/3 days; oral cyclosporin A 4 mg / Kg was
started on day - 1 and i.v. methotrexate 5 mg / m2 was delivered on
days  1,  3,  5 and  11. Median age of the patients was 19
years; there were 19 females. Patients received a median of 5.0 
106/ Kg CD34 cells. Results: Median time to achieve above 0.5 
109/L granulocytes was 14 days, whereas median time to achieve
above 20  109/L platelets was 15 days. Thirteen patients (30%)
are alive 491 days (median) after the HSCT. The 861-day proba-
bility of survival is 22%, whereas median survival is 200 days. Ten
patients (23%) developed acute graft versus-host disease (GVHD),
and 8 patients (18.6%) developed chronic GVHD. Twenty eight
(65%) patients showed relapse, in 9 cases despite the GVHD.
Thirty patients died between day 47 and 1050 after the HSCT,
most of them (70%) of an ALL relapse. The 100-day mortality was
25.5 %. Conclusion: Relapse remains the ﬁrst cause of death in
high-risk ALL patients. Non-myeloablative HCST seems to have
limited therapeutic effect in ALL patients with advanced disease.
New ideas and emerging strategies should be employed in order to
improve the outcome of these patients, like enhancement of graft-
versus leukemia effects and the use HSCT in ﬁrst complete remis-
sion.
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NEUROLOGICAL COMPLICATIONS IN THE RECIPIENTS OF ALLOGENEIC
HEMATOPOIETIC CELL TRANSPLANT
Siegal, D.1, Keller, A.2, Xu, W.3, Bhuta, S.2, Loach, D.1, Kim, D.1,
Walia, J.1, Kuruvilla, J.1, Lipton, J.1, Minden, M.1, Messner, H.1,
Gupta, V.1 1Blood and Marrow Transplant Program, Princess Margaret
Hospital, Toronto, ON, Canada; 2Department of Radiology, University
Health Network, Toronto; 3Department of Biostatistics, Princess Mar-
garet Hospital, Toronto.
The prevalence of neurological complications in allogeneic he-
matopoietic cell transplant (AlloHCT) recipients, the mechanisms
of its development, and its impact on outcome are not well deﬁned.
We reviewed the medical records of 302 consecutive patients, who
underwent AlloHCT for hematologic diseases at Princess Marga-
ret Hospital between January 2002 and November 2005. Patient,
disease and transplant related factors were systematically analyzed.
Stem cells were obtained via peripheral blood (n213) and bone
marrow (n89) from HLA-matched siblings/other family
(n224), HLA-matched unrelated donors (n52) and HLA-mis-
matched donors (n26). Median age of the recipients was 45 years
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